Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

UK patients offered app to report adverse reactions

Yellow Card app allows potential side-effects tobe sent directly to the MHRA

MHRA Yellow Card Scheme iPhone app

The UK has moved its Yellow Card Scheme into the mobile age, launching a smartphone app that allows patients to report potential side-effects and adverse reactions directly to the MHRA.

The medicines regulator's free new app - which is also aimed at carers and healthcare professionals - also allows users to select specific medicines or vaccines to track and receive news and alerts about them.

The iOS and Android app was created in collaboration with the Innovative Medicines Initiative's WEB-RADR project, which aims to boost biopharmaceutical innovation.

Life Sciences Minister George Freeman MP said: “The Yellow Card Scheme has played a vital role in the safety of medicines for the last 50 years and the launch of this new mobile app brings it into the 21st century.

“By making the scheme accessible to researchers, healthcare professionals and millions of patients, it will not only improve the safety of reporting but ultimately better protect people's health and support research in the NHS."

Its formation prompted by the Thalidomide safety scandal, the Yellow Card Scheme was set up to monitor the safety of UK medicines and act as an early warning system. It covers all licensed and unlicensed prescription medicines and vaccines, plus those bought over the counter from a pharmacist or supermarket.

20th July 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics